Search Results (177)

Adjuvants play a crucial role in increasing vaccination efficacy. While aluminum salts have historically been the most common adjuvants, recent research has turned to new compounds with enhanced adjuvant properties and improved safety. Cutting-edge nanotechnology, leveraging nanoformulations and novel delivery systems, has enhanced efficacy while reducing adverse effects. Microparticles, emulsions, and immunostimulants are now essential tools due to their significant potential for vaccine production. Additionally, advanced drug delivery systems (DDSs) have been developed using sophisticated technologies to expedite and optimize drug and vaccine delivery to specific target sites, thereby maximizing therapeutic efficacy and minimizing systemic accumulation. The latest DDSs offer numerous advantages over conventional drug delivery systems, including heightened performance, precision, and efficiency. These DDSs, comprising nanomaterials or miniaturized devices, feature multifunctional components that are biocompatible and biodegradable, with high viscoelasticity, thereby extending their circulating half-life. This review aims to provide an in-depth and up-to-date overview of adjuvants and technological advancements in vaccine delivery systems. Full article

Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable biopolymer widely used in advanced drug delivery systems (DDSs) due to its biocompatibility, controllable degradation behavior, and tunable physicochemical properties. Its degradation into naturally metabolized lactic and glycolic acids makes PLGA particularly attractive for biomedical applications, positioning PLGA nanoparticles as versatile carriers that bridge material design and therapeutic delivery. In this context, electrospray (electrohydrodynamic atomization) has emerged as an innovative and scalable processing technique that enables precise control over nanoparticle size, morphology, and internal structure under mild conditions, which is particularly suitable for engineering biopolymer-based DDSs. This review provides a comprehensive overview of electrospray-fabricated PLGA nanoparticles, with emphasis on the relationship between processing conditions, polymer structure, and functional performance. The fundamental mechanisms governing drug release, including diffusion, polymer degradation, and their combined effects, are discussed in relation to PLGA properties. The influence of electrospray parameters on nanoparticle formation, morphology, and internal architecture is analyzed, highlighting how process–structure–property relationships can be tailored to achieve specific release profiles. Structural design strategies, including single-matrix, core–shell, and surface-functionalized nanoparticles, are further examined as approaches to enable controlled and sequential dual-DDSs. In addition, emerging modeling and computational approaches are briefly discussed as complementary tools for understanding and optimizing nanoparticle behavior. Challenges and technical problems, such as substrates for nanoparticle detachment, are discussed. Full article

The review describes advances in stimulus-sensitive carriers for chemotherapy of various organs, since selectivity in cytotoxicity against cancer and normal cells is a key factor in effective cancer treatment. Special attention is devoted to particle carriers composed of natural compounds, such as lipids, phospholipids, oligopeptides, and synthetic macromolecules, that are sensitive to internal or external stimuli, and delivered to targeted body tissue in a controlled manner. The stimuli discussed include the following: temperature, pH, enzymes, electromagnetic radiation, ultrasound, and redox potential. The description of stimulus-sensitive drug delivery, the methods for synthesizing polymers and copolymers, and the preparation of nano- and microparticles are briefly presented. A description of drug delivery systems (DDSs) with controlled release to specific organs, such as the breast, intestine, lung, prostate, etc., is preceded by a description of methods for preparing drug carriers. The review also covers DDSs at various stages of preclinical and clinical trials and summarizes the state of knowledge on this subject. Full article

Lab-on-a-Chip (LoC) and microfluidic technologies are rapidly reshaping the development pipeline for nano drug delivery systems (DDSs) by enabling precise control of physicochemical properties, high-throughput screening, and integrated biological evaluation within miniaturized platforms. This review synthesizes recent advances in microfluidic principles, fabrication strategies, and sensing modalities that facilitate continuous flow synthesis, real-time characterization, and adaptive formulation of nanoparticles. We highlight how LoC-enabled systems improve monodispersity, reproducibility, and tunability of liposomes, polymeric nanoparticles, and metallic nanocarriers, while providing powerful tools for assessing pharmacokinetics, drug release, and systemic responses using organ-on-chip (OoC) models. Emerging trends, including AI-driven autonomous optimization, stimuli-responsive materials, 3D-printed hybrid architectures, and self-powered portable devices, are discussed in the context of future integrated nano-pharmaceutics platforms. Despite existing challenges related to biocompatibility, standardization, data integration, and translation to industrial and clinical applications, the synergistic evolution of LoC engineering and nanomedicine holds transformative potential for personalized and next-generation therapeutic strategies. Full article

Photodynamic therapy (PDT) is a promising localized strategy for the treatment of cervical cancer, ranking as the fourth most common cancer among women worldwide. The integration of photosensitizers (PSs) in localized drug delivery systems (DDSs), particularly in electrospun nanofibers, holds tremendous potential to overcome the drawbacks of their systemic administration. Exploring multilayer fibrous architectures provides a versatile therapeutic platform to design the next generation of localized DDS. In this work, localized implants for cancer treatment using PDT were developed using polyhydroxyalkanoate (PHA), chitosan (CS) and polyethylene oxide (PEO) as biopolymers and a porphyrin (Por) as PS, following two approaches: blended PHA/Por electrospun microfibers and multilayered membranes (PHA–Por/CS/PEO) produced by sequential electrospinning. The synthesized Por displayed higher cytotoxicity in light compared to dark against tumor cells. All the developed membranes were characterized regarding their morphology, wettability, absorption and fluorescence properties. PHA–Por membranes exhibited overall uniform fibrous morphologies with successful Por incorporation. Nonetheless, they presented a highly hydrophobic surface, compromising the Por release and cell–material interactions. In contrast, multilayer PHA–Por/CS/PEO membranes demonstrated enhanced hydrophilicity and enabled sustained Por release. Upon light irradiation, these membranes induced a significantly greater inhibition of HeLa cell proliferation (29.61%) compared to dark conditions (6.21%), confirming their photodynamic activity. Full article

Systemic anticancer therapy causes a number of side effects; therefore, local drug release devices may play an important role in this area. In this study, we developed polyurethane-dendrimer foams containing different amounts of third-generation poly (amidoamine) dendrimers (PAMAM G3) to evaluate their ability to encapsulate and release the model anticancer drug doxorubicin (DOX), as well as their biocompatibility and effectiveness against normal and cancer cells in vitro. PU–PAMAM foams containing 10–50 wt% PAMAM G3 were prepared using glycerin-based polyether polyol and castor oil as co-components. Structural and rheological analyses revealed that foams containing up to 20 wt% PAMAM G3 exhibited a well-developed porous structure, while higher dendrimer loadings (≥30 wt%) led to irregular cell shapes, pore coalescence, and thinning of cell walls, and indicated a gradual loss of structural integrity. Rheological creep–recovery measurements confirmed the structural findings: moderate PAMAM G3 incorporation (≤20 wt%) increased both the instantaneous and delayed elastic modulus (E₁ ≈ 130–140 kPa; E₂ ≈ 80 kPa) and enhanced elastic recovery, reflecting improved cross-link density and foam stability. Higher dendrimer contents (30–50 wt%) caused a decline in these parameters and higher viscoelastic compliance, indicating a softer, less stable structure. The DOX loading capacity and encapsulation efficiency increased with PAMAM G3 content, reaching maximum values of 35% and 51% for 30–40 wt% PAMAM G3, respectively. However, the most sustained DOX release profiles were observed for matrices containing 20 wt% PAMAM G3. Analysis of cumulative release and kinetic modeling revealed a transition from diffusion-controlled release at low PAMAM contents to burst-dominated release at higher dendrimer loadings. Importantly, matrices containing 10–20 wt% PAMAM G3 also indicated selective anticancer action against squamous cell carcinoma (SCC-15) compared to non-cancerous human keratinocytes (HaCaT). Moreover, the DOX they released effectively destroyed cancer cells. Overall, PU–PAMAM foams containing 10–20 wt% PAMAM G3 provide the most balanced combination of structural stability, controlled drug release, and cytocompatibility. These materials therefore represent a promising platform as passive carriers in drug delivery systems (DDSs), such as local implants, anticancer patches, or bioactive wound dressings. Full article

Background/Objectives: Advanced drug delivery systems (DDSs) are essential for targeted delivery, controlled release, and reduced systemic toxicity, but their clinical adoption is limited by biological barriers, manufacturing complexities, and cost. The aim of this systematic review is to critically evaluate the quantitative relationships between platform design, overcoming biological barriers, and clinical translation outcomes for DDS developed between 2016 and 2025. Methods: A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science (January 2016–April 2025) in accordance with the PRISMA 2020 guidelines. Included studies focused on experimental or clinical data for nanocarrier platforms (liposomes, lipid nanoparticles, polymer systems, biomimetic carriers, extracellular vesicles). Data on platform characteristics, interactions with barriers, pharmacokinetics, manufacturing, and clinical outcomes were extracted and synthesized in narrative form due to the significant methodological heterogeneity. Results: An analysis of 77 included studies confirms that successful clinical translation depends on matching the physicochemical properties of the carrier (size, surface chemistry, material) to specific biological barriers. Liposomes and lipid nanoparticles (LNPs) remain the most clinically validated platforms, exploiting the EPR effect and liver tropism, respectively. Key engineering solutions include stealth coatings, ligand-mediated targeting, and stimulus-responsive materials to overcome barriers such as mononuclear phagocyte system clearance, the blood–brain barrier, and mucosal barriers. Microfluidic and continuous manufacturing processes enable reproducibility, but scalability, cost, and immunogenicity (e.g., anti-PEG responses) remain key translational challenges. Engineered extracellular vesicles, biomimetic carriers, and 3D/4D-printed systems combined with AI-driven design demonstrate the potential for personalized, adaptive delivery. Conclusions: Cutting-edge DDSs have validated their clinical value, but realizing their full potential requires a holistic, patient-centered design approach integrating barrier-specific engineering, scalable manufacturing, and rigorous safety assessment from the earliest stages of development. Further progress will depend on standardizing methods for new platforms (e.g., extracellular vesicles), implementing digital and AI tools, and ensuring translational feasibility as a fundamental principle. Full article

Chitosan (CS) has emerged as a versatile biopolymer for designing drug delivery systems (DDS) in colorectal cancer (CRC) therapy due to its biocompatibility, mucoadhesive properties, and ability to be surface-functionalized. This scoping review systematically analyzed current experimental studies on CS-based DDS for CRC, comparing non-targeted formulations with ligand-modified systems to identify advances in targeting efficiency, drug release behavior, and biological outcomes. Among the twenty-five initially identified studies, divided into two categories, non-targeted CS-based DDSs and ligand-modified CS-DDSs, five fulfilled the inclusion criteria for ligand-functionalized systems. These incorporated targeting moieties, such as folic acid (FA), hyaluronic acid (HA), and galactose (Gal), to achieve receptor-mediated uptake via FRα, CD44, and ASGP receptors, respectively. Ligand modification consistently enhanced cellular uptake, reduced IC₅₀ values, and improved tumor-selective cytotoxicity compared to non-targeted systems. However, in vivo validation remains scarce, with only one study confirming tumor accumulation in xenograft models. Moreover, no clinical trials currently assess CS-based nanocarriers for the treatment of CRC. Overall, CS represents a promising modular platform for targeted nanomedicine, but translational progress requires bridging preclinical success with comprehensive in vivo and clinical evaluation. Full article

Artificial intelligence (AI) is transforming pharmaceutical science by shifting drug delivery research from empirical experimentation toward predictive, data-driven innovation. This review critically examines the integration of AI across formulation design, smart drug delivery systems (DDSs), and sustainable pharmaceutics, emphasizing its role in accelerating development, enhancing personalization, and promoting environmental responsibility. AI techniques—including machine learning, deep learning, Bayesian optimization, reinforcement learning, and digital twins—enable precise prediction of critical quality attributes, generative discovery of excipients, and closed-loop optimization with minimal experimental input. These tools have demonstrated particular value in polymeric and nano-based systems through their ability to model complex behaviors and to design stimuli-responsive DDS capable of real-time therapeutic adaptation. Furthermore, AI facilitates the transition toward green pharmaceutics by supporting biodegradable material selection, energy-efficient process design, and life-cycle optimization, thereby aligning drug delivery strategies with global sustainability goals. However, challenges persist, including limited data availability, lack of model interpretability, regulatory uncertainty, and the high computational cost of AI systems. Addressing these limitations requires the implementation of FAIR data principles, physics-informed modeling, and ethically grounded regulatory frameworks. Overall, AI serves not as a replacement for human expertise but as a transformative enabler, redefining DDS as intelligent, adaptive, and sustainable platforms for future pharmaceutical development. Compared with previous reviews that have considered AI-based formulation design, smart DDS, and green pharmaceutics separately, this article integrates these strands and proposes a dual-framework roadmap that situates current AI-enabled DDS within a structured life-cycle perspective and highlights key translational gaps. Full article

In the last decade, notable developments have occurred regarding the application of membrane vesicles—encompassing extracellular vesicles (EVs, including exosomes, microvesicles, apoptotic bodies, and others), self-organized cellular-membrane-derived vesicles, and isolated cell-bound membrane vesicles, among others—as bioinspired drug delivery systems (DDSs). A collection of 10 papers on such advances was published in the Special Issue of Pharmaceutics entitled “Advances of membrane vesicles in drug delivery systems, 2nd Edition”. These papers investigate the Minimum Information for Studies of Extracellular Vesicles (MISEV), in vivo fluorescence imaging and tracking, in vivo specific tissue targeting, and the therapeutic application of membrane vesicles as DDSs in cancers, osteoarthritis, ocular disorders, intestinal disease, and kidney diseases. The present article briefly summarizes these related topics and provides novel insights into the research on membrane vesicles as DDSs. Full article

Silica aerogel has garnered significant attention in the biomedical field, primarily due to its unique combination of a three-dimensional structure, low density, tunable nanoscale pores, and an extensive surface area. These intrinsic properties render it as an exceptional candidate for advanced drug delivery systems (DDSs). In the realm of medical applications, silica aerogels have demonstrated remarkable potential, especially in nanoscale DDSs. Traditional drug delivery methods, such as capsules and tablets, are often plagued by several drawbacks, including poor bioavailability, lack of target specificity, and multidrug resistance. These limitations necessitate the development of more efficient and targeted drug delivery systems. Recent advancements in the synthesis and modification of silica aerogels have significantly enhanced their biocompatibility and functionalization capabilities. These improvements have further bolstered their potential for controlled release and targeted delivery of therapeutic agents. This study is based on silica aerogel-based nanocarrier systems, providing an in-depth exploration of its fundamental principles, preparation processes, and recent advancements. Based on this, we summarize the drug delivery methods, drug release characteristics, and diverse medical applications of silica aerogels. Additionally, we discuss the challenges and future prospects of applying silica aerogels in drug delivery systems, aiming to provide a comprehensive overview of this field. Full article

In this study, non-toxic, biodegradable, and pH-sensitive polyurethane hydrogels (PUs) were prepared by using hexamethylene diisocyanate (HDI), copolymers of є-caprolactone (CL), rac-lactide (LA), and poly(ethylene glycol) (PEG), poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (PEO-bPPO-b-PEO), 1,4-butanediol (BD), and L-glutamine (Gln). The CL, LA, and PEG copolymers were obtained in the presence of a new synthesized catalytic system: diethylzinc/ethyl-3,4-dihydroxybenzoate. Obtained PUs were screened for their cytotoxicity, evaluated for their swelling behavior and hydrolytic degradation, and employed as hydrogel pH-responsive anti-cancer drug delivery systems (DDSs). The novel and promising hydrogel DDSs, capable of releasing 5-fluorouracyl (5-FU) and fluorodeoxyuridine (5-fluoro-2′-deoxyuridine, FUdR) in a sustained and controlled manner, were prepared and were nontoxic. Most prepared hydrogel DDSs were found to release anti-cancer drugs with first-order or zero-order kinetics. The drug release mechanism was generally denoted as Fickian or non-Fickian transport. The possibility of controlling the kinetics of drug release by changing the pH of the environment was also observed. The findings indicate that these PU hydrogels are suitable for use as intelligent DDSs for the targeted delivery of 5-FU or FUdR. We expect that the hydrogel DDSs developed will be utilized in the treatment of pancreatic cancer. Full article

Biodegradable polymers such as Polycaprolactone (PCL), Polylactic acid (PLA), and Poly(lactic-co-glycolic acid) (PLGA) are attracting attention as key platforms for anticancer drug delivery systems due to their excellent biocompatibility and controllable degradation rates. These polymers can overcome limitations of existing chemotherapeutics, such as low bioavailability, systemic toxicity, and nonspecific cell damage, and contribute to the development of precision medicine approaches and long-acting therapeutics. This paper discusses the chemical and physicochemical properties of these three polymers, their synthetic strategies, and the controlled drug release technology through surface functionalization and stimuli-responsive design. Furthermore, we highlight their potential for use in various formulations, including micelles, nanoparticles, hydrogels, and microspheres, enabling enhanced drug solubility, sustained release, and tumor targeting. Preclinical and clinical applications demonstrate that these polymer-based DDSs represent a promising approach for implementing next-generation precision anticancer treatment strategies, with further potential for clinical translation and widespread adoption. Full article

Inflammatory bowel disease (IBD) is a chronic, heterogeneous condition characterized by recurrent intestinal inflammation and sustained mucosal barrier damage, profoundly impairing patients’ quality of life and imposing a considerable socioeconomic burden. Current therapeutic options are often constrained by low oral bioavailability, pronounced systemic toxicity, and inadequate tissue specificity, limiting their ability to achieve precise and durable efficacy. In recent years, membrane vesicle-based drug delivery systems (MV-DDSs) have shown considerable promise for precision IBD therapy owing to their excellent biocompatibility, mucosal barrier-penetrating capacity, and low immunogenicity. Building upon a systematic discussion of the roles of MV-DDSs in suppressing inflammatory signaling, modulating oxidative stress, preserving barrier integrity, reshaping the gut microbiota, and regulating programmed cell death, this review further compares the differences in key molecular targets and functional outcomes among vesicles of diverse origins and carrying distinct therapeutic payloads. These insights provide a comprehensive strategic reference and theoretical foundation for the rational design, mechanistic optimization, and clinical translation of MV-DDSs in IBD therapy. Full article

Oral mucositis (OM) is a severe inflammatory condition of the oral mucosa that is commonly associated with cancer therapies. Traditional treatments typically have limited efficacy and significant side effects, necessitating alternative approaches. Nanobased drug delivery systems (DDSs) present promising solutions, enhancing therapeutic outcomes while minimizing side effects. This review aims to evaluate the use of nanobased DDSs to treat OM. To reach these aims, an extensive literature review was conducted using the following databases: BVS, PubMed, Scopus, and Web of Science. The search strategy included the keywords “microparticles,” “nanoparticles,” “drug delivery system,” “oral mucositis,” “therapy,” and “treatment,” combined with the Boolean operators “AND” and “OR.” After applying filters for language, relevance, full-text availability, exclusion of review articles, and removal of duplicates, a total of 32 articles were selected for analysis. Of the 32 studies included in this review, 25 employed polymeric micro- or nanosystems for the treatment of OM. Regarding the stage of investigation, 10 studies were conducted in vitro, 16 were conducted in vivo, and 6 corresponded to clinical trials. Compared with conventional drug delivery approaches, most of these studies reported improved therapeutic outcomes. These findings highlight the potential of nanosystems as innovative strategies for enhancing OM treatment. Nonetheless, challenges in large-scale manufacturing, including reproducibility and safety, and the limited number of clinical trials warrant careful consideration. Future research with larger clinical trials is essential to validate these findings and effectively guide clinical practice. Full article